Elevated levels of cerebrospinal fluid (CSF) AMPH have been documented in some studies of patients with Alzheimer’s Disease (AD) and mild cognitive impairment (MCI) who exhibit abnormal tau levels. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.